JMJoseph K. McLaughlin

Joseph K. McLaughlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph K. McLaughlin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Loren Lipworth

    International Epidemiology Institute, Rockville, MD 20850, USA

    10 shared publications
  • Robert E. Tarone

    International Epidemiology Institute, Rockville, MD

    7 shared publications
  • Søren Friis

    From the *International Epidemiology Institute, Rockville, Maryland, MD; †Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN; ‡Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; and §Department of Plastic Surgery, Copenhagen University Hospital, Herlev, Denmark

    4 shared publications
  • Jon P. Fryzek

    International Epidemiology Institute, Rockville, MD 20850, USA

    3 shared publications
  • Jørgen Helge Olsen

    Danish Cancer Society Research Center, Copenhagen, Denmark

    3 shared publications
  • Kim Kjøller

    From the *International Epidemiology Institute, Rockville, Maryland, MD; †Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN; ‡Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; and §Department of Plastic Surgery, Copenhagen University Hospital, Herlev, Denmark

    3 shared publications

Latest Publications

  • Psychological Characteristics of Danish Women With Cosmetic Breast Implants

    by Loren ScD Lipworth, Kim Kjøller, Lisbet R. Hölmich, Søren Friis, Jørgen H. Md Olsen, Joseph K. McLaughlin

    An excess of suicide among women with cosmetic breast implants compared with controls has consistently been reported in epidemiologic studies. We have evaluated psychological characteristics among 423 Danish women with cosmetic breast implants, compared with 414 controls. Odds ratios (OR) with 95% confidence intervals (CI) for self-reported psychological symptoms were calculated using multiple logistic regression. Substantial excesses of all studied symptoms before implant surgery were reported among women with breast implants compared with women with other cosmetic surgery, whereas ORs for virtually all symptoms occurring after surgery were close to or below 1.0. In particular, ORs for treatment for depression, cognitive/depressive symptoms, and depression/low spirit before surgery were 4.6 (95% CI = 2.1–10.0), 3.9 (95% CI = 1.9–7.8), and 2.5 (95% CI = 1.1–5.5), respectively. In contrast, the corresponding ORs for these 3 psychological symptoms after surgery were 0.9 (95% CI = 0.6–1.4), 1.0 (95% CI = 0.7–1.5), and 1.0 (95% CI = 0.6–1.5), respectively. In conclusion, women with cosmetic breast implants reported preoperative psychological symptoms indicative of depressive disorders substantially more frequently than women with other cosmetic surgery. Future studies using standardized, validated psychiatric assessment tools are needed to determine whether this can explain the higher risk for suicide among a subset of women seeking cosmetic breast implants.


  • Open Access

    Cancer among Scandinavian women with cosmetic breast implants: A pooled long-term follow-up study

    by Loren Lipworth, Robert E. Tarone, Søren Friis, Weimin Ye, Jørgen H. Olsen, Olof Nyren, Joseph K. McLaughlin

    No increased risks of specific types of cancer following breast implantation have been consistently reported, but data on risk beyond 15 years are limited. We have pooled the results of 2 nationwide cohort studies of 3,486 Swedish and 2,736 Danish women who underwent cosmetic breast implantation between 1965 and 1993. Cancer incidence through 2002 was ascertained through nationwide cancer registries. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated to compare cancer incidence among women with implants with women in the general population. Mean duration of follow up was 16.6 years (range 0.1–37.8 years). Over 50% of women were followed for 15 years or more after breast implantation and 13.3% for at least 25 years. There was a reduced incidence of breast cancer (SIR = 0.73; 95% CI 0.58–0.90), whereas lung cancer was above expectation (SIR = 1.64; 95% CI 1.10–2.36). The increased risk of lung cancer is expected due to the high prevalence of smoking among the women with implants in our study. With respect to other site‐specific cancers, no significantly increased or decreased SIR was observed. This study, which includes women followed for almost 4 decades, represents the longest follow up of women with cosmetic breast implants to date. The results provide no evidence of an association between breast implants and any type of cancer.


  • The risk of cholecystitis in patients with cancer and the general population in a population-based cohort study in Western Denmark, 1995–2003

    by J. P. Fryzek, R. W. Thomsen, H. F. Thomsen, M. Nørgaard, K. Cetin, J. K. McLaughlin, R. E. Tarone, H. T. Sørensen

    20598 Background: Little information is available on the risk of cholecystitis among patients with cancer. Methods: We conducted a population-based retrospective cohort study of 51,350 patients with incident cancer, identified in medical databases of Western Denmark between 1995 and 2003. A general population comparison cohort of 513,500 persons frequency-matched on the age and sex distribution of the cancer cohort was assembled from the Danish Civil Registration System. The incidence of cholecystitis in the two cohorts was determined by linkage to the regional Hospital Discharge Registry covering all hospitals in the region. Results: We identified 230 incident diagnoses of cholecystitis in our cancer cohort during 130,628 person-years of follow-up, corresponding to an incidence rate of 1.8/1000 person-years. After adjustment for potential confounders, the adjusted relative risk (aRR) for cholecystitis among cancer patients compared with the general population cohort was 1.38 (95% confidence interval (CI) 1.20–1.58). Overall, the aRR for cholecystitis was doubled during the first six months after cancer diagnosis (aRR=1.95, 95% CI 1.50–2.54), at which point the aRR declined but remained greater than 1 throughout the rest of the follow-up period (aRR=1.23, 95% CI 1.05–1.45). Age-specific adjusted RRs ranged from 1.44 to 2.11 among cancer patients up to 70 years of age but were only marginally increased in cancer patients aged greater than 70 years. There were no major differences in aRRs between metastatic and non-metastatic cancer patients. Pancreatic cancer (aRR=6.71, 95% CI 3.82–11.76), thyroid cancer (aRR=3.83, 95% CI 1.60–9.22), and colorectal cancer (aRR=2.06, 95% CI 1.33–3.20) conferred the highest adjusted relative risks for subsequent cholecystitis. Conclusions: Cholecystitis occurs more often in cancer patients than in the general population. Pancreatic, thyroid and colorectal cancer seem to confer an especially high relative risk for subsequent cholecystitis, particularly during the first six months following diagnosis and among younger patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Inc. Amgen Inc.

  • The Safety of Silicone Gel-Filled Breast Implants

    by Joseph K. McLaughlin, Loren Lipworth, Diane K. Murphy, Patricia S. Walker

    Few implantable medical devices have been studied for their safety more extensively than silicone gel-filled breast implants. We summarize the epidemiologic evidence on the safety of breast implants, most of which is drawn from large cohort studies with long-term follow-up. The topics addressed in this report include cancer, breast cancer detection, connective tissue disease, suicide, offspring effects, neurologic disease, implant rupture, and local perioperative complications and additional surgery. We conclude that the weight of the epidemiologic evidence does not support a causal association between breast implants and breast or any other type of cancer, definite or atypical connective tissue disease, adverse offspring effects, or neurologic disease. Women with breast implants do not present with more advanced stages of breast cancer or suffer impaired survival after breast cancer diagnosis. The only study to examine an actual incidence rate of breast implant rupture reported rupture-free survival of 98% at 5 years and 83%–85% at 10 years for newer “third-generation” implants. Future studies are needed to determine whether the consistently observed excess of suicide among women with implants reflects underlying psychiatric illness prior to breast augmentation surgery or other factors.


  • RE: Alleged secret ties to industry

    by Joseph K. McLaughlin, John D. Boice, Robert E. Tarone, William J. Blot


  • A Nationwide Study of Connective Tissue Disease and Other Rheumatic Conditions Among Danish Women With Long-Term Cosmetic Breast Implantation

    by Jon P. Fryzek, Lisbet Holmich, Joseph K. McLaughlin, Loren Lipworth, Robert E. Tarone, Trine Henriksen, Kim Kjøller, Søren Friis


  • A rebuttal: Secret ties to industry and conflicting interests in cancer research

    by Joseph K. McLaughlin, John D. Boice, Robert E. Tarone, William J. Blot


  • Epidemiologic Aspects of Renal Cell Carcinoma

    by Joseph K. McLaughlin, Loren Lipworth, Robert E. Tarone


  • Open Access

    Long-Term Cancer Risk Among Swedish Women With Cosmetic Breast Implants: An Update of a Nationwide Study

    by Joseph K. McLaughlin, Loren Lipworth, Jon P. Fryzek, Weimin Ye, Robert E. Tarone, Olof Nyren

    Epidemiologic evidence does not support a consistently increased cancer risk among women with cosmetic breast implants, but few studies have assessed risk beyond 15 years. Swedish women who underwent cosmetic breast implantation for the first time between January 1, 1965, and December 31, 1993 ( N = 3486), were followed through December 31, 2002. Cancer incidence was ascertained through the nationwide Swedish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated to compare cancer incidence of women with implants with women in the general population. Mean follow-up among women with breast implants was 18.4 years (range = 0.1–37.8 years). The incidence of breast cancer was below expectation (SIR = 0.7, 95% CI = 0.6 to 1.0), whereas lung cancer was above expectation (SIR = 2.2, 95% CI = 1.3 to 3.4). With respect to cancer overall and all other specific cancer sites, including brain cancer and sarcoma, non-Hodgkin lymphoma, and multiple myeloma, no statistically significantly increased or decreased SIRs were observed. Stratification by duration of follow-up revealed no statistically significantly increased or decreased SIR, with the exception of a two- to threefold excess of lung cancer among women followed for more than 15 years, which would be expected due to the high prevalence of smoking among the Swedish women with implants in our study.